German Drugmaker Boehringer Ingelheim Teams with Virus Therapies Specialist ViraTherapeutics.
28 September 2016 - German drugmaker Boehringer Ingelheim and Austrian biopharmaceutical company ViraTherapeutics have inked a long-term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) alone and in combination with other therapies, the companies said.
ViraTherapeutics, a company specialising in the development of oncolytic virus therapies, has developed its novel technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and will now be responsible for preclinical and clinical testing of VSV-GP in Phase I trials.
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development.
Oncolytic virus therapy is a cancer treatment approach that uses a virus that infects and breaks down cancer cells.
Tumor antigens that are normally hidden from the immune system inside the cells are released, triggering an immune response to fight the tumor.
VSV-GP has a shorter replication time than other oncolytic virus platforms currently under development.
This oncolytic virus does not integrate in the DNA and has been modified to avoid neural inflammation associated with wild type viruses.
In VSV-GP the glycoprotein of the Vesicular Stomatitis Virus has been replaced by the glycoprotein of the Lymphocytic Choriomeningitis Virus to conceal the virus from the immune system.
In preclinical models it did not induce virus neutralising antibodies, potentially enabling repeated administration.
ViraTherapeutics GmbH (ViraT) is a privately held biopharmaceutical company developing promising innovative virus-based immunotherapeutics for the treatment of cancer.
The company was founded in 2013 as a spin-out of the Medical University of Innsbruck by Prof. Dr. Dorothee von Laer, head of the Virology Division at the university.
ViraT develops oncolytic cancer vaccines based on a chimeric virus derived from the Vesicular Stomatitis Virus, so called VSV-GP.
Buyer: Boehringer Ingelheim
Deal size in USD:
Buyer advisor: , ,
Comment: Terms of the deal were not disclosed
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Sep 28, 2016|
|Previous Article:||Car Dealer Group Morgan Auto Acquires Florida's Rountree-Moore Motors.|
|Next Article:||Deal snapshot: TECH AIR ACQUIRES LIQUID TECHNOLOGY, JW GOODLIFFE AND SON.|